Turn Therapeutics (TTRX) Income from Continuing Operations (2024 - 2026)
Turn Therapeutics (TTRX) posted quarterly Income from Continuing Operations of 3146464.0 for Q1 2026, down 449.34% year-over-year from 900696.34 in Q1 2025, and down 7.5% quarter-over-quarter from 2927074.0 in Q4 2025.
Powered by 
Analysis
Turn Therapeutics (TTRX) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Turn Therapeutics' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 3146464.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 449.34% year-over-year to 3146464.0; the TTM figure through Mar 2026 stood at 14222169.0 (changed N/A YoY), while the FY2025 annual figure was 13904726.0, down 146.3% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3146464.0, down from 2927074.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 470237.0 in Q4 2024, with the low at 7575856.0 in Q3 2025.
- The 3-year median for Income from Continuing Operations is 1976403.0 (2024), against an average of 2619689.67.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations plunged 638.58% in 2025, then slumped 449.34% in 2026.
- Turn Therapeutics' Income from Continuing Operations stood at 470237.0 in 2024, then slumped by 522.47% to 2927074.0 in 2025, then declined by 7.5% to 3146464.0 in 2026.
- Business Quant data shows TTRX's Income from Continuing Operations at 3146464.0 in Q1 2026, 2927074.0 in Q4 2025, and 7575856.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Turn Therapeutics | 302.05 Mn | 302.05 Mn | - | -1.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.87 Mn |
| Mar 31, 2026 | -1.74 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -1.91 Mn |
| Jun 30, 2025 | -1.36 Mn |
| Mar 31, 2025 | -572,775.00 |
| Dec 31, 2024 | -323,130.00 |
| Sep 30, 2024 | -666,442.00 |